Martin Gebel

2.8k total citations · 1 hit paper
37 papers, 1.6k citations indexed

About

Martin Gebel is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Martin Gebel has authored 37 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Cardiology and Cardiovascular Medicine, 23 papers in Internal Medicine and 8 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Martin Gebel's work include Venous Thromboembolism Diagnosis and Management (23 papers), Atrial Fibrillation Management and Outcomes (21 papers) and Hormonal Regulation and Hypertension (8 papers). Martin Gebel is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (23 papers), Atrial Fibrillation Management and Outcomes (21 papers) and Hormonal Regulation and Hypertension (8 papers). Martin Gebel collaborates with scholars based in Germany, Canada and United States. Martin Gebel's co-authors include Luís M. Ruilope, Bertram Pitt, Stefan D. Anker, Peter Rossing, George L. Bakris, Gerasimos Filippatos, Amer Joseph, Rajiv Agarwal, Christina Nowack and Peter Kolkhof and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Journal of the American College of Cardiology.

In The Last Decade

Martin Gebel

33 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

2021 578 citations Rajiv Agarwal, Gerasimos Filippatos et al. European Heart Journal profile →

Peers

Countries citing papers authored by Martin Gebel

Since Specialization

Citations

This map shows the geographic impact of Martin Gebel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Gebel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Gebel more than expected).

Fields of papers citing papers by Martin Gebel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Gebel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Gebel. The network helps show where Martin Gebel may publish in the future.

Co-authorship network of co-authors of Martin Gebel

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Gebel. A scholar is included among the top collaborators of Martin Gebel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Gebel. Martin Gebel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes By Diuretic Use: A FIDELITY Analysis 2025 ·European Journal of Heart Failure ·Robert J. Mentz, Stefan D. Anker, Bertram Pitt, Peter Rossing, Luís M. Ruilope, Martin Gebel, Peter Kolkhof, Robert Lawatscheck, Katja Rohwedder, George L. Bakris	0
2	Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials 2024 ·Journal of the American College of Cardiology ·John W. Eikelboom, Hardi Mundl, John H. Alexander, Valeria Caso, Stuart J. Connolly, Rosa Coppolecchia, Martin Gebel, Robert G. Hart, Gerlind Holberg, (unknown), Manesh R. Patel, Jonathan P. Piccini, Sunil V. Rao, Ashkan Shoamanesh, Miriam Tamm, Thomas Viethen, Ashraf Yassen, Marc P. Bonaca	4
3	A Survey to Assess the Current Status of Structured Benefit-Risk Assessment in the Global Drug and Medical Device Industry 2024 ·Therapeutic Innovation & Regulatory Science ·Martin Gebel, Cheryl Renz, Lisa Rodríguez, Arianna Simonetti, Hong Yang, Brian Edwards, (unknown), (unknown), Michael W. Colopy	3
4	Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis 2023 ·European Heart Journal - Cardiovascular Pharmacotherapy ·Gerasimos Filippatos, Stefan D. Anker, Phyllis August, Andrew J.S. Coats, James L. Januzzi, Boris Mankovsky, Peter Rossing, Luís M. Ruilope, Bertram Pitt, Pantelis Sarafidis, John R. Teerlink, Chris J. Kapelios, Martin Gebel, Meike Brinker, Amer Joseph, Andrea Lage, George L. Bakris, Rajiv Agarwal	24
5	Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone 2023 ·JAMA Cardiology ·Rajiv Agarwal, Bertram Pitt, Peter Rossing, Stefan D. Anker, Gerasimos Filippatos, Luís M. Ruilope, Csaba P. Kövesdy, Katherine R. Tuttle, Muthiah Vaduganathan, Christoph Wanner, Sameer Bansilal, Martin Gebel, Amer Joseph, Robert Lawatscheck, George L. Bakris	21
6	A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease 2022 ·Clinical Kidney Journal ·Rajiv Agarwal, Bertram Pitt, Biff F. Palmer, Csaba P. Kövesdy, Ellen Burgess, Gerasimos Filippatos, Jolanta Małyszko, Luís M. Ruilope, Patrick Rossignol, Peter Rossing, Roberto Pecoits‐Filho, Stefan D. Anker, Amer Joseph, Robert Lawatscheck, Daniel J. Wilson, Martin Gebel, George L. Bakris	57
7	Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism 2022 ·Journal of Thrombosis and Haemostasis ·Ingrid M. Bistervels, (unknown), Martin Gebel, Anthonie W.A. Lensing, Saskia Middeldorp, Martin H. Prins, Michiel Coppens	6
8	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis breakdown → 2021 ·European Heart Journal ·Rajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, Stefan D. Anker, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Martin Gebel, Luís M. Ruilope, George L. Bakris, (unknown)	578
9	Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies 2021 ·Research and Practice in Thrombosis and Haemostasis ·Sylvia Haas, LG Mantovani, Reinhold Kreutz, (unknown), Jonas Schneider, Elizabeth R. Zell, Miriam Tamm, Martin Gebel, (unknown), Walter Ageno, Alexander G.G. Turpie	12
10	XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America 2019 ·Thrombosis Research ·Reinhold Kreutz, LG Mantovani, Sylvia Haas, (unknown), Jonas Schneider, (unknown), Martin Gebel, Miriam Tamm, Walter Ageno, Alexander G.G. Turpie	13
11	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin 2018 ·Thrombosis Research ·Paolo Prandoni, Anthonie W.A. Lensing, Martin H. Prins, Martin Gebel, Ákos F. Pap, Martin Homering, Rupert Bauersachs, Jan Beyer‐Westendorf, Henri Bounameaux, Alexander T. Cohen, Bruce L. Davidson, Bonno van Bellen, Peter Verhamme, Philip S. Wells, Žhong Yuan, Bennett Levitan, Jeffrey I. Weitz	11
12	Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis 2018 ·European Journal of Internal Medicine ·LG Mantovani, Sylvia Haas, Reinhold Kreutz, Kerstin Folkerts, Martin Gebel, (unknown), Jonas Schneider, Martin van Eickels, Kurtuluş Şahin, Elizabeth R. Zell, Walter Ageno, Alexander G.G. Turpie	3
13	A Pooled Analysis of the Xalia and Xalia-Lea Non-Interventional Studies of Rivaroxaban Versus Standard Anticoagulation in Venous Thromboembolism 2017 ·Blood ·Alexander G.G. Turpie, LG Mantovani, Sylvia Haas, Reinhold Kreutz, (unknown), Jonas Schneider, Martin van Eickels, Miriam Tamm, Martin Gebel, Walter Ageno	2
14	Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study 2017 ·Thrombosis Research ·Alexander G.G. Turpie, LG Mantovani, Sylvia Haas, Reinhold Kreutz, (unknown), Jonas Schneider, Martin van Eickels, Martin Gebel, Walter Ageno	8
15	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE 2016 ·CHEST Journal ·Philip S. Wells, Martin H. Prins, Bennett Levitan, Jan Beyer‐Westendorf, Timothy Brighton, Henri Bounameaux, Alexander T. Cohen, Bruce L. Davidson, Paolo Prandoni, Gary E. Raskob, Žhong Yuan, Eva G. Katz, Martin Gebel, Anthonie W.A. Lensing	26
16	Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients 2015 ·Thrombosis and Haemostasis ·Martin Gebel, Kurtuluş Şahin, Anthonie W.A. Lensing, Karina Meijer, (unknown)	10
17	Structured Benefit–risk assessment: a review of key publications and initiatives on frameworks and methodologies 2015 ·Pharmaceutical Statistics ·Shahrul Mt‐Isa, Mario Ouwens, Véronique Robert, Martin Gebel, Alexander Schacht, Ian Hirsch	30
18	Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study 2015 ·The Lancet Haematology ·Walter Ageno, LG Mantovani, Sylvia Haas, Reinhold Kreutz, (unknown), Jonas Schneider, Martin van Eickels, Martin Gebel, Elizabeth R. Zell, Alexander G.G. Turpie	186
19	3D- und Farbdopplersonographische Evaluation einer am Pankreaskopf gelegenen zystischen Raumforderung* 2008 ·Ultraschall in der Medizin - European Journal of Ultrasound ·B Boozari, Martin Gebel, J. Bleck, (unknown), M Caselitz, Johann Ockenga, Michael Ott, J. Schubert, (unknown), Michael P. Manns, M. Galanski	0
20	Occupational risks for adenocarcinoma of the nasal cavity and paranasal sinuses in the German wood industry 2007 ·Occupational and Environmental Medicine ·Beate Pesch, Christiane Barbara Pierl, Martin Gebel, (unknown), Daniela Becker, Georg Johnen, (unknown), K Donhuijsen, (unknown), Martin Meier, Johannes Schulze, Thomas Brüning	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact